Thomas Woiwode - 12 May 2021 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Reporting relationship: Director
Issuer ticker: ADVM
Reported as of: 12 May 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 May 2021, 20:05:38 UTC
Next SEC filing: 28 May 2021
Source filing: View source filing
Reporting owner signature: Thomas Woiwode, by /s/ Ron A. Metzger, Attorney-in-Fact

Key filing fact

Thomas Woiwode filed Form 4 for Adverum Biotechnologies, Inc. (ADVM) on 14 May 2021.

Key facts

This page summarizes Thomas Woiwode's Form 4 filing for Adverum Biotechnologies, Inc. (ADVM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 May 2021, 20:05.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADVM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 12 May 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $3.70
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.